Table 4.
Characteristics of COVID-19 patients who did not receive remdesivir.
| Patients characteristics (N = 159) | N | (%) |
|---|---|---|
| Age, years, median (range) | 71 (23–94) | |
| Sex | ||
| Male | 82 | 51.6 |
| Female | 77 | 48.4 |
| Race | ||
| Japanese | 140 | 88.1 |
| East-Asian | 4 | 2.5 |
| South-Asian | 6 | 3.8 |
| Lationo | 1 | 0.6 |
| Caucasian | 7 | 4.4 |
| Mix | 1 | 0.6 |
| Severity of illness categories by NIH classification | ||
| Asymptomatic | 4 | 2.5 |
| Mild | 22 | 13.8 |
| Moderate | 60 | 37.7 |
| Severe | 48 | 30.2 |
| Critical | 25 | 15.7 |
| Steroid dose | ||
| Steroid pulse | 18 | 11.3 |
| Non-pulse | 56 | 35.2 |
| No | 85 | 53.5 |
| Comorbidities | ||
| Diabetes mellitus | 44 | 28.0 |
| Hypertension | 47 | 29.9 |
| Hyperlipidemia | 28 | 17.8 |
| D-dimer, µg/mL | ||
| Normal | 34 | 21.7 |
| Elevated (> 1.0 μg/mL) | 112 | 71.3 |
| Unexamined | 13 | 8.3 |
| Increase in pancreatic enzyme levels | ||
| Grade 3 | 3 | 1.9 |
| Grade 4 | 0 | 0 |
| Outcome | ||
| Discharged | 143 | 89.9 |
| Death | 15 | 9.4 |
| Hospitalized | 1 | 0.6 |
Baseline demographic and clinical characteristics of 157 patients who did not received remdesivir between February 5, 2020 and January 31, 2021.